object
longterm
dynam
antibodi
respons
patient
influenza
viru
infect
well
understood
method
conduct
longitudin
serolog
followup
studi
patient
hospit
viru
infect
virusspecif
antibodi
respons
assess
hemagglutin
inhibit
hai
neutral
nt
assay
random
intercept
model
use
fit
curv
hai
antibodi
respons
time
hai
antibodi
respons
compar
clinic
sever
result
patient
viru
infect
hai
antibodi
titer
reach
averag
day
ill
onset
peak
titer
three
month
averag
titer
present
month
month
respect
hai
antibodi
respons
significantli
higher
patient
experienc
sever
diseas
includ
respiratori
failur
acut
respiratori
distress
syndrom
compar
patient
experienc
less
sever
ill
conclus
patient
viru
infect
surviv
sever
diseas
mount
higher
antibodi
respons
persist
longer
period
compar
experienc
moder
diseas
studi
convalesc
plasma
treatment
patient
consid
collect
donor
plasma
survivor
sever
diseas
month
ill
onset
human
infect
avian
influenza
viru
first
identifi
spring
china
caus
human
infect
avian
influenza
viru
juli
total
laboratoryconfirm
human
case
includ
death
report
world
health
organ
although
four
human
case
viru
infect
report
sinc
octob
viru
detect
declin
poultri
viru
far
erad
notabl
virus
continu
assess
repres
moder
high
public
health
risk
rank
highest
among
influenza
virus
animalorigin
unit
state
center
diseas
control
prevent
influenza
risk
assess
tool
laboratoryconfirm
case
viru
infect
sever
ill
requir
icu
admiss
earli
neuraminidas
inhibitor
treatment
appear
shorten
durat
viral
shed
improv
outcom
virusinfect
patient
howev
emerg
neuraminidas
inhibitor
resist
avian
influenza
virus
highlight
need
addit
therapeut
option
convalesc
plasma
may
potenti
treatment
sever
influenza
use
treatment
one
patient
respond
oseltamivir
treatment
convalesc
plasma
postvaccin
plasma
also
use
treatment
patient
beigel
colleagu
conduct
first
random
control
trial
immun
plasma
sever
season
influenza
report
evid
clinic
benefit
primarili
limit
particip
treat
within
day
ill
onset
larger
phase
iii
trial
ongo
although
promis
sever
safeti
concern
practic
challeng
use
convalesc
plasma
includ
defin
optim
time
sera
collect
recoveri
ill
casetocas
heterogen
antibodi
titer
rapid
evolut
influenza
virus
limit
understand
specif
kinet
durat
antibodi
respons
human
infect
virus
therefor
current
imped
develop
evalu
convalesc
plasma
therapi
et
al
describ
dynam
antibodi
respons
viru
year
post
ill
onset
patient
also
character
antibodi
respons
viru
month
ill
onset
crosssect
analysi
howev
longitudin
dynam
antibodi
respons
beyond
one
year
determin
conduct
longitudin
followup
studi
patient
hospit
viru
infect
object
character
specif
kinet
durat
antibodi
respons
patient
viru
infect
examin
associ
antibodi
respons
clinic
sever
explor
time
plasma
collect
plasma
therapi
recruit
follow
patient
revers
transcript
polymeras
chain
reaction
rtpcr
confirm
influenza
viru
infect
six
provinc
china
beij
shandong
zhejiang
hunan
jiangxi
fujian
three
epidem
epidem
hospit
discharg
patient
enrol
epidem
jiangxi
provinc
demograph
inform
clinic
data
hospit
collect
use
standard
form
underli
medic
condit
associ
high
risk
complic
influenza
defin
report
previous
patient
classifi
sever
ill
experienc
acut
respiratori
distress
syndrom
ard
requir
mechan
ventil
patient
enrol
hospit
obtain
avail
residu
sera
collect
clinic
laboratori
test
patient
also
follow
discharg
obtain
addit
sampl
addit
recruit
follow
patient
discharg
serum
sampl
collect
enrol
followup
visit
occur
month
ill
onset
among
serum
sampl
fiftyf
specimen
collect
hospit
discharg
patient
epidem
test
report
previou
studi
investig
virusspecif
antibodi
respons
cell
memori
survivor
within
year
follow
ill
onset
studi
protocol
review
approv
ethic
committe
school
public
health
fudan
univers
ethic
committe
chines
center
diseas
control
prevent
written
inform
consent
obtain
particip
serolog
assay
perform
joint
institut
virolog
shantou
universityth
univers
hong
kong
antigen
use
revers
genet
reconstruct
virus
includ
low
pathogen
viru
strain
gene
deriv
wildtyp
viru
ahong
yrd
lineag
hemagglutinin
neuraminidas
gene
wildtyp
viru
six
intern
gene
apuerto
highli
pathogen
viru
strain
yrd
lineag
remov
multipl
basic
amino
acid
motif
hemagglutinin
cleavag
site
three
virus
candid
vaccin
virus
propos
sampl
patient
epidem
test
viru
repres
virus
isol
human
epidem
hemagglutin
inhibit
hai
assay
neutral
nt
assay
perform
accord
standard
protocol
seroposit
threshold
defin
hai
antibodi
titer
neutral
antibodi
titer
nonreact
titer
defin
valu
see
supplementari
data
detail
analys
kinet
antibodi
respons
associ
clinic
outcom
pool
serolog
data
patient
rtpcrconfirm
viru
infect
three
epidem
hai
neutral
antibodi
titer
log
transform
analys
comparison
gmt
sever
ill
patient
moder
ill
patient
perform
mannwhitney
u
test
cluster
sampl
time
ill
onset
also
use
linear
regress
model
adjust
sex
age
sampl
time
ill
onset
previou
studi
report
patient
viru
infect
lower
neutral
antibodi
titer
hai
antibodi
titer
neutral
antibodi
titer
lower
patient
compar
patient
also
observ
lower
neutral
antibodi
titer
compar
hai
antibodi
titer
studi
use
random
intercept
linear
model
bspline
analyz
dynam
hai
antibodi
respons
neutral
antibodi
respons
time
sera
virusinfect
patient
degre
knot
bspline
select
base
akaik
inform
criterion
aic
gener
estim
equat
gee
model
use
fit
dynam
curv
antibodi
titer
april
septemb
total
patient
hospit
laboratoryconfirm
viru
infect
enrol
supplementari
fig
includ
fourteen
particip
epidem
fortyon
epidem
twelv
epidem
supplementari
fig
eighteen
patient
enrol
hospit
four
die
hospit
two
lost
followup
fortynin
patient
recruit
follow
hospit
discharg
serial
visit
discharg
conduct
month
month
month
month
diseas
onset
fortynin
patient
epidem
singl
visit
conduct
month
ill
onset
patient
epidem
number
particip
blood
sampl
differ
stage
shown
fig
total
serum
sampl
collect
supplementari
fig
includ
one
seven
specimen
patient
patient
provid
least
two
sampl
tabl
demograph
clinic
featur
enrol
patient
hospit
shown
tabl
among
patient
male
median
age
year
old
subject
data
avail
least
one
highrisk
chronic
medic
condit
common
clinic
complic
includ
pneumonia
respiratori
failur
ard
fortyon
percent
patient
requir
mechan
ventil
fortyf
percent
patient
requir
intens
care
unit
icu
admiss
median
durat
hospit
type
diabet
chronic
respiratori
diseas
neurolog
diseas
chronic
liver
diseas
chronic
renal
diseas
anemia
underli
medic
condit
mutual
exclus
patient
day
iqr
major
differ
patient
characterist
observ
three
epidem
four
patient
epidem
die
hospit
tabl
hai
neutral
geometr
mean
antibodi
titer
gmt
lower
respect
fig
convalesc
sera
patient
epidem
nonreact
viru
fig
supplementari
tabl
patient
serum
sampl
collect
hospit
develop
hai
antibodi
titer
hospit
median
day
rang
day
ill
onset
patient
hai
antibodi
titer
hospit
develop
hai
antibodi
titer
discharg
median
day
rang
day
ill
onset
hai
antibodi
titer
patient
remain
even
discharg
day
one
patient
day
anoth
patient
fig
greater
rise
hai
antibodi
titer
note
seven
nine
patient
pair
serum
sampl
collect
hospit
occur
median
day
ill
onset
initi
specimen
rang
day
median
day
rang
day
ill
onset
specimen
serum
specimen
collect
critic
ill
patient
fatal
outcom
hai
antibodi
titer
day
ill
onset
hai
antibodi
titer
neutral
antibodi
titer
hospit
recoveri
lower
moder
ill
patient
treat
oseltamivir
compar
patient
receiv
oseltamivir
treatment
includ
sever
ill
supplementari
fig
ill
onset
hai
gmt
reach
within
day
peak
day
gmt
persist
month
fig
b
contrast
increas
neutral
antibodi
titer
delay
fig
c
appli
cutoff
valu
proport
seroposit
hai
antibodi
ci
day
ill
onset
greater
thereaft
one
year
ill
onset
supplementari
fig
neutral
antibodi
undetect
month
ill
onset
appli
cutoff
valu
seroposit
rate
increas
ci
day
ci
month
ill
onset
supplementari
fig
hai
antibodi
titer
correl
neutral
antibodi
titer
rho
p
indic
moder
posit
correl
supplementari
fig
correl
coeffici
hai
antibodi
titer
neutral
antibodi
titer
rho
moder
posit
correl
lower
observ
ahong
rho
strongli
posit
correl
supplementari
fig
hai
antibodi
titer
correl
accord
model
mean
hai
antibodi
level
reach
titer
day
day
ill
onset
fig
peak
three
month
gmt
fig
b
declin
titer
month
month
fig
c
neutral
antibodi
titer
increas
slower
hai
antibodi
titer
reach
small
peak
day
gmt
decreas
slightli
continu
increas
month
ill
onset
hai
antibodi
titer
decreas
throughout
period
supplementari
fig
day
month
ill
onset
hai
antibodi
titer
sever
ill
patient
progress
ard
requir
mechan
ventil
significantli
higher
unadjust
analys
fig
model
adjust
sex
age
time
sampl
ill
onset
p
associ
factor
clinic
outcom
also
analyz
age
older
year
corticosteroid
treatment
significantli
associ
sever
ill
univari
analys
corticosteroid
treatment
associ
sever
ill
multivari
analys
supplementari
tabl
studi
patient
hospit
virologicallyconfirm
viru
infect
epidem
mount
strong
serum
hai
antibodi
respons
viru
hospit
recoveri
estim
mean
virusspecif
hai
antibodi
titer
peak
three
month
ill
onset
remain
month
sever
ill
patient
mount
higher
antibodi
respons
hospit
persist
long
period
recoveri
therefor
studi
convalesc
plasma
treatment
patient
consid
collect
donor
plasma
survivor
sever
diseas
month
ill
onset
kinet
virusspecif
hai
antibodi
respons
hospit
patient
similar
describ
studi
patient
cohort
patient
provid
blood
sampl
hospit
hai
antibodi
titer
hospit
studi
et
al
patient
hai
antibodi
titer
hospit
recoveri
therefor
patient
viru
infect
surviv
sever
diseas
abl
mount
detect
hai
antibodi
level
differ
peak
time
hai
antibodi
titer
analys
gmt
model
analysi
might
due
inadequ
sampl
contact
virologicallyconfirm
case
investig
serolog
studi
patient
serolog
evid
viru
reinfect
recoveri
epidemiolog
investig
patient
surviv
viru
infect
across
five
epidem
group
also
found
reoccurr
relatedil
reinfect
viru
report
longitudin
seroepidemiolog
studi
analysi
estim
mean
hai
antibodi
titer
remain
month
ill
onset
et
al
report
hai
gmt
declin
lower
month
ill
onset
howev
use
human
viru
isol
test
serum
sampl
patient
epidem
might
result
underestim
antibodi
titer
anoth
crosssect
studi
et
al
report
hai
gmt
near
month
ill
onset
similar
find
pool
analys
antibodi
kinet
data
antigen
antigenicallymatch
circul
strain
prefer
howev
might
antigenspecif
differ
hai
titer
could
affect
result
adopt
two
statist
approach
investig
question
evalu
main
effect
interact
effect
antigen
model
found
effect
statist
signific
construct
model
hai
result
viru
formula
knot
model
pool
analysi
supplementari
fig
month
ill
onset
trend
averag
curv
virusonli
model
similar
model
pool
result
subsequ
former
curv
decreas
slower
later
one
howev
due
lack
sera
avail
month
month
ill
onset
test
virusonli
model
view
model
pool
data
reliabl
find
antigenspecif
differ
hai
respons
affect
model
significantli
could
due
small
sampl
size
addit
investig
need
data
avail
differ
antigen
studi
small
number
case
fatal
outcom
preclud
statist
comparison
antibodi
titer
fatal
case
vs
nonfat
case
virusspecif
antibodi
respons
patient
hospit
zhang
et
al
report
neutral
antibodi
titer
increas
faster
survivor
fatal
case
howev
statist
signific
differ
antibodi
titer
fatal
vs
nonfat
case
found
anoth
patient
cohort
virusspecif
antibodi
respons
discharg
survivor
et
al
found
associ
diseas
sever
antibodi
respons
one
studi
report
sever
diseas
associ
higher
hai
titer
discharg
anoth
studi
antibodi
respons
viru
infect
recoveri
report
lower
patient
asymptomat
infect
sever
ill
previou
studi
viru
infect
patient
indic
effect
crossreact
cell
memori
import
protect
sever
influenza
diseas
caus
newli
emerg
influenza
virus
therefor
lack
suffici
cell
respons
might
result
prolong
viral
replic
cytokin
dysregul
sever
diseas
higher
antibodi
respons
patient
hpai
virus
antigen
distinct
lpai
virus
includ
determin
use
postinfect
ferret
antisera
lu
et
al
report
sera
collect
week
ill
onset
patient
lpai
clade
viru
infect
react
hpai
human
isol
although
lower
titer
homolog
viru
sinc
lack
virolog
data
identifi
specif
viru
strain
infect
patient
test
serum
sampl
patient
epidem
three
distinct
viru
strain
patient
posit
serolog
respons
like
infect
lpai
virus
convalesc
sera
patient
collect
month
ill
react
develop
neutral
antibodi
respons
delay
compar
hai
antibodi
respons
neutral
antibodi
titer
continu
increas
longer
period
recoveri
zhang
et
al
report
increas
neutral
antibodi
respons
within
week
ill
onset
use
pseudovirusbas
neutral
assay
howev
result
pseudovirusbas
neutral
assay
might
correl
well
result
authent
virusbas
neutral
test
studi
guo
et
al
neutral
antibodi
detect
sampl
collect
day
ill
onset
consist
find
et
al
also
observ
delay
neutral
antibodi
respons
infect
gmt
increas
overtim
peak
day
observ
discord
viru
hai
neutral
antibodi
respons
hai
antibodi
respons
decreas
peak
month
neutral
antibodi
respons
increas
long
clinic
recoveri
correl
hai
neutral
antibodi
respons
vari
viru
antigen
greater
correl
recent
ahong
viru
compar
older
antigen
distinct
viru
vaccin
induc
compar
level
hareact
igg
antibodi
season
influenza
vaccin
mice
neutral
titer
low
suggest
larg
compon
induc
antibodi
respons
nonneutr
phenomenon
might
attribut
intern
gene
viru
nevertheless
neutral
nonneutr
antibodi
induc
vaccin
human
protect
mice
vivo
stringent
lethal
challeng
therefor
neutral
antibodi
titer
may
underestim
protect
effect
antibodi
respons
follow
viru
infect
convalesc
plasma
therapi
shown
promis
treatment
varieti
emerg
infecti
diseas
includ
pandem
influenza
influenza
influenza
sever
acut
respiratori
syndrom
sar
time
treatment
patient
sever
ill
hyperimmun
iv
immunoglobulin
hivig
reduc
mortal
timetotreat
effect
requir
time
avail
viru
specif
convalesc
plasma
high
antibodi
titer
shown
implement
passiveimmunotherapi
program
logist
feasibl
influenza
pandem
kreil
et
al
demonstr
feasibl
produc
hivig
prepar
larg
scale
rel
rapidli
could
improv
reduc
lowtit
donat
use
convalesc
plasma
transfus
hivig
product
hai
antibodi
titer
donor
plasma
need
dose
gkg
would
need
hivig
treatment
three
plasmapheresi
donat
donat
ml
plasma
time
could
produc
enough
plasma
treatment
two
three
patient
median
durat
viral
shed
day
ill
onset
nonfat
patient
recov
median
day
indic
convalesc
plasma
could
collect
month
ill
onset
collect
blood
survivor
sever
ill
viru
infect
month
ill
onset
yield
convalesc
plasma
hai
antibodi
titer
suitabl
convalesc
plasma
therapi
hivig
product
among
patient
enrol
studi
sever
ill
survivor
age
year
old
make
suitabl
potenti
blood
donor
plasma
therapi
anoth
potenti
sourc
convalesc
plasma
particip
clinic
trial
vaccin
howev
sinc
virus
continu
evolv
antigen
distinct
strain
regardless
sourc
plasma
import
determin
level
crossreact
antibodi
convalesc
plasma
patient
viru
infect
understand
whether
treatment
like
benefici
furthermor
administr
convalesc
plasma
treatment
patient
viru
infect
ideal
done
control
clinic
trial
studi
sever
limit
first
particip
symptomat
diseas
requir
hospit
magnitud
kinet
antibodi
respons
patient
milder
ill
asymptomat
infect
might
differ
second
clinic
data
avail
patient
hospit
might
impact
analys
third
abl
collect
serial
serum
specimen
patient
hospit
limit
test
remain
avail
sera
survivor
follow
design
time
point
fourth
respiratori
specimen
character
virus
infect
patient
determin
viral
load
durat
shed
associ
diseas
sever
antibodi
respons
final
patient
follow
studi
may
repres
survivor
viru
infect
china
howev
includ
patient
provinc
epidem
sinc
conclus
establish
largest
cohort
survivor
date
follow
year
determin
specif
kinet
longev
virusspecif
antibodi
convalesc
plasma
treatment
pursu
clinic
trial
find
indic
plasma
could
prepar
blood
survivor
sever
diseas
homolog
viru
strainspecif
infect
collect
approxim
month
ill
onset
h
receiv
investigatoriniti
research
fund
sanofi
pasteur
glaxosmithklin
yichang
hec
changjiang
pharmaceut
compani
none
research
fund
relat
research
human
infect
avian
influenza
virus
author
declar
compet
interest
